147 related articles for article (PubMed ID: 25955490)
1. Zoledronic acid enhances antitumor efficacy of liposomal doxorubicin.
Hattori Y; Shibuya K; Kojima K; Miatmoko A; Kawano K; Ozaki K; Yonemochi E
Int J Oncol; 2015 Jul; 47(1):211-9. PubMed ID: 25955490
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II-induced hypertension enhanced therapeutic efficacy of liposomal doxorubicin in tumor-bearing mice.
Hattori Y; Ubukata H; Kawano K; Maitani Y
Int J Pharm; 2011 Jan; 403(1-2):178-84. PubMed ID: 20934498
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages.
Hattori Y; Yamashita J; Sakaida C; Kawano K; Yonemochi E
J Liposome Res; 2015; 25(2):131-40. PubMed ID: 25203609
[TBL] [Abstract][Full Text] [Related]
5. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
[TBL] [Abstract][Full Text] [Related]
6. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.
Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH
Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791
[TBL] [Abstract][Full Text] [Related]
7. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model.
Ishida T; Shiraga E; Kiwada H
J Control Release; 2009 Mar; 134(3):194-200. PubMed ID: 19095022
[TBL] [Abstract][Full Text] [Related]
10. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
[TBL] [Abstract][Full Text] [Related]
11. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
[TBL] [Abstract][Full Text] [Related]
12. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
[TBL] [Abstract][Full Text] [Related]
13. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
14. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
15. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
Harasym TO; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
[TBL] [Abstract][Full Text] [Related]
16. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
17. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
[TBL] [Abstract][Full Text] [Related]
19. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
Salzano G; Marra M; Porru M; Zappavigna S; Abbruzzese A; La Rotonda MI; Leonetti C; Caraglia M; De Rosa G
Int J Pharm; 2011 Jan; 403(1-2):292-7. PubMed ID: 21055454
[TBL] [Abstract][Full Text] [Related]
20. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
